Related Experiment Video
Updated: Jul 16, 2026
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Jessica C Song1, Clifford C Wang, Yi-Chao Huang
1University of the Pacific School of Pharmacy, Stockton, CA, USA. jessica.song@hhs.co.santa-clara.ca.us
Insights
Maximum-dose statin therapy (simvastatin or atorvastatin) did not achieve low-density-lipoprotein cholesterol goals in high-risk, ethnically diverse patients. Monitoring for adverse events and drug interactions was inadequate, indicating suboptimal statin use.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- High-intensity statin therapy is crucial for managing cardiovascular risk.
- Ethnic diversity influences lipid metabolism and drug response.
- Understanding statin efficacy and safety in diverse populations is essential for optimal patient outcomes.
Purpose of the Study:
- To evaluate the effectiveness and monitoring of maximum-dose simvastatin or atorvastatin in an ethnically diverse patient population.
- To assess low-density-lipoprotein (LDL) cholesterol goal attainment in high-risk individuals.
- To identify adverse events and drug interactions associated with high-intensity statin use.
Main Methods:
- Retrospective analysis of outpatients receiving maximum-dose simvastatin or atorvastatin.
- Inclusion of patients from a predominantly Hispanic and Asian population at a teaching institution.
- Evaluation of demographic data, cardiovascular risk factors, laboratory values, and adverse event documentation.
Main Results:
- Only 19.4% of very-high-risk and 44.1% of high-risk patients achieved LDL cholesterol goals.
- Thirteen patients experienced myalgia; alanine transaminase levels were monitored in only 38.8% of patients.
- Approximately 9% of patients were on interacting medications, most commonly gemfibrozil.
Conclusions:
- Maximum-dose statin therapy failed to meet LDL cholesterol targets in this high-risk, diverse cohort.
- Inadequate monitoring of statin therapy and potential for drug interactions were observed.
- Clinical practice may require improved strategies for optimizing statin therapy in ethnically diverse populations.
Purpose:
The use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population was studied.
Methods:
This retrospective analysis was conducted at a publicly funded teaching institution whose predominant patient population consists of Hispanics and Asians. A computer-generated report was used to identify outpatients who received a prescription for maximum-dose simvastatin or atorvastatin between January 1, 2002, and January 1, 2004. Data evaluated included demographic information; metabolic syndrome elements; coronary heart disease (CHD) risk equivalents; clinical characteristics placing patients at very high risk of having a CHD event; 10-year Framingham risk score; documentation of hepatotoxicity, myalgia, myositis, or rhabdomyolysis during maximum-dose therapy; concomitant medication during maximumdose therapy; relevant laboratory test values; and physician response to biochemical abnormalities or adverse events associated with maximum-dose therapy.
Results:
Of the 232 outpatients identified, 173 were eligible for study inclusion. A total of 135 patients were classified as having a high or very-high risk of developing CHD (68 and 67, respectively). The success rates for low-density-lipoprotein (LDL) cholesterol goal attainment by very-high-risk patients and high-risk patients were 19.4% and 44.1%, respectively. Thirteen patients developed myalgia. Alanine transaminase levels were monitored for 38.8% of the study patients. Approximately 9% of patients were prescribed one interacting medication while on maximum-dose simvastatin or atorvastatin. The most commonly prescribed interacting drug was gemfibrozil.
Conclusion:
Despite the use of maximum-dose simvastatin or atorvastatin, target LDL cholesterol goals were not achieved and statin use was not adequately monitored in an ethnically diverse population with a high or very high risk of developing CHD.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:21Drug Dosing: Obese Patients
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
01:15Drug Dosing: Geriatric Patients
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies